What Lecanemab Meant for One Family: Larry’s Experience With Treatment
When a loved one is diagnosed with mild cognitive impairment or Alzheimer’s-related changes, families often find themselves asking the same difficult question: is there anything that can help slow things down?
For Larry, taking part in a Lecanemab trial became one possible answer.
He was diagnosed with mild cognitive impairment (MCI) in 2018 following an MRI scan. In 2020, he was able to join the Lecanemab trial and began receiving an IV infusion every two weeks through the Memory Assessment and Research Centre in Southampton.
His story offers something many families are looking for: not false certainty, but a real-life example of what treatment can look like in practice.
What happened after diagnosis
A diagnosis of mild cognitive impairment can bring mixed emotions. For some people, it offers relief because there is finally a name for what has been happening. For others, it brings fear about what may come next.
MCI does not mean everyone will go on to develop dementia at the same rate, but it can be an early sign that changes are happening. That uncertainty can be difficult to live with. Families may feel stuck between wanting to stay positive and wanting to prepare.
In Larry’s case, joining the trial gave him access to a treatment route and a clearer plan moving forward.
What treatment involved
Lecanemab treatment was not a one-off event. Larry received infusions every two weeks, showing the level of commitment that can come with this type of treatment. Clinical pathways like this can involve hospital visits, monitoring, follow-up appointments and regular testing.
That structure can feel reassuring for some families. For others, it may feel tiring or logistically difficult. Much depends on the person’s health, support network, location and how manageable the routine feels over time.
After the first trial ended, it was confirmed that Larry had been receiving the drug rather than the placebo. He then continued with the trial through to the end of the year.
How Larry feels it helped
Larry believes the drug has helped to slow the progression of his symptoms. He has not experienced side effects, and his memory tests, taken every six months, have not changed much during that time.
For families living with cognitive decline, “not changing much” can mean a great deal. Stability matters. Holding on to day-to-day independence, social connection and routines can have a real impact on quality of life.
Larry says he is still able to live a full life, including bike rides and spending time with family and friends. That detail is powerful because it shifts the conversation away from illness alone and back towards life. The goal for many people is not simply more time, but more good time.
Why stories like this matter to caregivers
Caregivers are often trying to balance hope with realism. They do not want exaggerated promises, but they also do not want to feel that nothing can be done. Personal stories like Larry’s can be helpful because they show one person’s experience in a grounded way.
At the same time, it is important to remember that no treatment works in exactly the same way for everyone. Response, suitability and access vary, and decisions about treatment are always personal and medical.
What stories like this can do is open the door to better conversations. They can help families ask informed questions, explore options and feel less alone in trying to understand new developments.
The challenge of access
Although Larry’s experience has been positive, access remains a major issue. Lecanemab and Donanemab are not available on the NHS because NICE ruled that their benefits were not high enough to justify the cost.
That can be incredibly difficult for families to hear. When a treatment appears promising, but is not widely available, it can leave people feeling frustrated, helpless or left behind.
This is one of the painful realities of dementia care. Research may move forward, but access often does not move at the same pace. For caregivers, that can add another layer of emotional strain to an already demanding journey.
Questions families may want to ask
If you are caring for someone with MCI or early Alzheimer’s-related symptoms, it may help to ask healthcare professionals questions such as:
What treatment options are currently available to us?
Are there any clinical trials or research opportunities we should know about?
What monitoring would treatment involve?
How might benefits and risks be weighed in this individual case?
What support is available while we consider our options?
You do not need to become an expert overnight, but having a list of questions can make appointments feel more manageable.
A hopeful but realistic takeaway
Larry’s experience with Lecanemab offers cautious hope. He feels the treatment has helped to slow the progression of symptoms, he has experienced no side effects and he is still living a full life with meaningful activities and relationships.
For caregivers, that matters. It is a reminder that research is moving, that some people are seeing benefits and that the future of dementia treatment may not look exactly the same as the past.
At the same time, it is okay to hold both hope and disappointment together. Hope that new treatments are emerging, and disappointment that access remains limited. Both feelings can exist at once.
If you are supporting someone with memory changes, keep asking questions, keep seeking clarity and keep making space for the person behind the diagnosis.
